Industry News
Pharmaceutical Industry News
RTI Health Solutions leaders…
RTI Health Solutions leaders explain how patient voices are reshaping evidence generation, access and value communication
The LeonaBio rebrand comes from…
The LeonaBio rebrand comes from the name Leona, which means lioness and reflects the company's "commitment to leadership, resilience, and innovation," CEO Mark Litton, Ph.D., said.
Orca Bio has disclosed $250…
Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the commercialization of a blood cancer cell therapy.
Add Johnson & Johnson to the…
Add Johnson & Johnson to the list of biopharma giants that have struck most-favored-nation (MFN) drug pricing deals with the Trump administration. The company also announced plans to build new manufacturing facilities in Pennsylvania and
Early launch numbers of Brinsupri…
Early launch numbers of Brinsupri are so strong that Insmed couldn’t wait for the J.P. Morgan Healthcare Conference to share them. The first-in-class inflammatory drug shattered Wall Street estimates in its first full quarter on
The next phase of Novartis’ $23…
The next phase of Novartis' $23 billion U.S. investment drive will center on a 35,000-square-foot radioligand therapy (RLT) facility in Winter Park, Florida. Joining established plants in Novartis’ American RLT network in Indiana, New Jersey
UCB, AbbVie and Legend Biotech are…
UCB, AbbVie and Legend Biotech are among the companies presenting at the JPM conference today. We'll keep you up to speed throughout the day in this tracker.
Today will feature presentations…
Today will feature presentations from Big Pharmas including GSK, AstraZeneca and Novo Nordisk, and Fierce's own event kicks off at the Hyatt Regency. Be sure to check in all day to stay on top of
After a flurry of Big Pharma deals…
After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco for the industry's biggest investor event of the year. Be sure
Trump Says He ‘Probably Should’ Take Obesity Drugs, but Has Not
President Trump has talked in the past about people he knows who have taken “the fat drug.”
In the past three weeks, a flurry…
In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring, AbbVie, AstraZeneca, Servier, Sanofi and Ipsen. Shionogi also beefed up its rare disease portfolio with a $2.5 billion deal
As evidence of tirzepatide’s…
As evidence of tirzepatide’s efficacy mounts across a range of cardiometabolic conditions, Eli Lilly has shown that taking the incretin medicine alongside another of its drugs, Taltz, could lead to better outcomes for patients living
In a saga that has spread over…
In a saga that has spread over seven years, the FDA has again rejected Vanda’s bid to expand the label for Hetlioz to treat jet lag disorder. The new rejection came three months after the
Shortly after floating a…
Shortly after floating a contingency plan for its asset, vilobelimab—which boasts an emergency use authorization for COVID-19 in the U.S.—Germany’s InflaRx is drafting bigger changes to its organization as it looks to cut costs and
Suarez will return to the U.S. as…
Suarez will return to the U.S. as SVP and president, head of the U.S. biopharmaceuticals business unit, after five years posted in Madrid as head of the company's Spain division.
Mind Medicine has altered its…
Mind Medicine has altered its state, rebranding as Definium Therapeutics ahead of a series of phase 3 data drops on its lead psychedelic drug candidate.
Acuitas Therapeutics shelled out…
Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics in a move to scale the latter's operations around high-end RNA constructs used to
Novo Nordisk has begun a vital…
Novo Nordisk has begun a vital year for its weight-loss franchise with a push to understand how obesity hits differently depending on factors such as culture, gender and generation. The research informed an exhibit in
Salesforce’s Mark Sullivan…
Salesforce’s Mark Sullivan explains why trust, data discipline and human oversight will determine who wins in an agent-driven future.
Though Gilead Sciences made waves…
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting treatment for the viral infection. Now,